Neurochemical Research

, Volume 38, Issue 9, pp 1777–1784 | Cite as

Glia Maturation Factor Expression in Entorhinal Cortex of Alzheimer’s Disease Brain

  • Ramasamy Thangavel
  • Duraisamy Kempuraj
  • Deirdre Stolmeier
  • Poojya Anantharam
  • Mohammad Khan
  • Asgar Zaheer
Original Paper


Alzheimer’s disease (AD) is characterized by the presence of neuropathological lesions containing amyloid plaques (APs) and hyperphosphorylated Tau containing neurofibrillary tangles (NFTs) and is associated with neuroinflammation and neurodegeneration. Entorhinal cortex (Brodmann’s area 28) is involved in memory associated functions and is one of the first brain areas targeted to form the neuropathological lesions and also severely affected cortical region in AD. Glia maturation factor (GMF), a central nervous system protein and a proinflammatory molecule is known to be up-regulated in the specific areas of AD brain. Our previous immunohistochemical studies using temporal cortex showed that GMF is expressed in the vicinity of APs and NFTs in AD brains. In the present study, we have analyzed the expression of GMF and its association with APs and NFTs in the entorhinal cortex of AD brains by using immunohistochemistry combined with thioflavin-S fluorescence labeling methods. Results showed that GMF immunoreactive glial cells, glial fibrillary acidic protein labeled reactive astrocytes and ionized calcium binding adaptor molecule-1 labeled activated microglia were increased in the entorhinal cortical layers especially at the sites of 6E10 labeled APs and Tau containing NFTs. In conclusion, increased expression of GMF by the glial cells in the entorhinal cortex region, and the co-localization of GMF with APs and NFTs suggest that GMF may play important proinflammatory roles in the pathogenesis of AD.


Alzheimer’s disease  Amyloid plaques  Entorhinal cortex  Glia maturation factor  Neurofibrillary tangles  Neuroinflammation 



This work was supported by the Department of Veterans Affairs Merit Review award (to A.Z.) and by the National Institute of Neurological Disorders and Stroke grants NS073670 (to A.Z.).


  1. 1.
    Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427–434PubMedCrossRefGoogle Scholar
  2. 2.
    Streit WJ, Braak H, Xue QS, Bechmann I (2009) Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease. Acta Neuropathol 118:475–485PubMedCrossRefGoogle Scholar
  3. 3.
    Thangavel R, Stolmeier D, Yang X, Anantharam P, Zaheer A (2012) Expression of glia maturation factor in neuropathological lesions of Alzheimer’s disease. Neuropathol Appl Neurobiol 38:572–581PubMedCrossRefGoogle Scholar
  4. 4.
    Lace G, Savva GM, Forster G, de Silva R, Brayne C et al (2009) Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain 132:1324–1334PubMedCrossRefGoogle Scholar
  5. 5.
    Thangavel R, Van Hoesen GW, Zaheer A (2009) The abnormally phosphorylated tau lesion of early Alzheimer’s disease. Neurochem Res 34:118–123PubMedCrossRefGoogle Scholar
  6. 6.
    Kolarova M, Garcia-Sierra F, Bartos A, Ricny J, Ripova D (2012) Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimer’s Dis 2012:731526Google Scholar
  7. 7.
    Lee G, Thangavel R, Sharma VM, Litersky JM, Bhaskar K et al (2004) Phosphorylation of tau by fyn: implications for Alzheimer’s disease. J Neurosci 24:2304–2312PubMedCrossRefGoogle Scholar
  8. 8.
    Bevilaqua LR, Rossato JI, Bonini JS, Myskiw JC, Clarke JR et al (2008) The role of the entorhinal cortex in extinction: influences of aging. Neural plast 2008:595282PubMedCrossRefGoogle Scholar
  9. 9.
    Van Hoesen GW, Hyman BT, Damasio AR (1991) Entorhinal cortex pathology in Alzheimer’s disease. Hippocampus 1:1–8PubMedCrossRefGoogle Scholar
  10. 10.
    Gomez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH et al (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500PubMedGoogle Scholar
  11. 11.
    deToledo-Morrell L, Stoub TR, Bulgakova M, Wilson RS, Bennett DA et al (2004) MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 25:1197–1203PubMedCrossRefGoogle Scholar
  12. 12.
    Hof PR, Bussiere T, Gold G, Kovari E, Giannakopoulos P et al (2003) Stereologic evidence for persistence of viable neurons in layer II of the entorhinal cortex and the CA1 field in Alzheimer disease. J Neuropath Exp Neur 62:55–67PubMedGoogle Scholar
  13. 13.
    Porchet R, Probst A, Bouras C, Draberova E, Draber P et al (2003) Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer’s disease. Proteomics 3:1476–1485PubMedCrossRefGoogle Scholar
  14. 14.
    Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA et al (2009) Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropath Exp Neur 68:774–784PubMedCrossRefGoogle Scholar
  15. 15.
    Nelson PT, Dimayuga J, Wilfred BR (2010) Micro RNA in situ hybridization in the human entorhinal and transentorhinal cortex. Front Hum Neurosci 4:7PubMedCrossRefGoogle Scholar
  16. 16.
    Lim R, Miller JF, Zaheer A (1989) Purification and characterization of glia maturation factor beta: a growth regulator for neurons and glia. Proc Natl Acad Sci USA 86:3901–3905PubMedCrossRefGoogle Scholar
  17. 17.
    Lim R, Zaheer A, Lane WS (1990) Complete amino acid sequence of bovine glia maturation factor beta. Proc Natl Acad Sci USA 87:5233–5237PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan R, Zaheer A, Jaye M, Lim R (1991) Molecular cloning and expression of biologically active human glia maturation factor-beta. J Neurochem 57:483–490PubMedCrossRefGoogle Scholar
  19. 19.
    Zaheer A, Sahu SK, Wu Y, Haas J, Lee K et al (2007) Diminished cytokine and chemokine expression in the central nervous system of GMF-deficient mice with experimental autoimmune encephalomyelitis. Brain Res 1144:239–247PubMedCrossRefGoogle Scholar
  20. 20.
    Zaheer A, Zaheer S, Thangavel R, Wu Y, Sahu SK et al (2008) Glia maturation factor modulates beta-amyloid-induced glial activation, inflammatory cytokine/chemokine production and neuronal damage. Brain Res 1208:192–203PubMedCrossRefGoogle Scholar
  21. 21.
    Zaheer S, Thangavel R, Sahu SK, Zaheer A (2011) Augmented expression of glia maturation factor in Alzheimer’s disease. Neuroscience 194:227–233PubMedCrossRefGoogle Scholar
  22. 22.
    Thangavel R, Van Hoesen GW, Zaheer A (2008) Posterior parahippocampal gyrus pathology in Alzheimer’s disease. Neuroscience 154:667–676PubMedCrossRefGoogle Scholar
  23. 23.
    Thangavel R, Sahu SK, Van Hoesen GW, Zaheer A (2008) Modular and laminar pathology of Brodmann’s area 37 in Alzheimer’s disease. Neuroscience 152:50–55PubMedCrossRefGoogle Scholar
  24. 24.
    Thangavel R, Sahu SK, Van Hoesen GW, Zaheer A (2009) Loss of nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in Alzheimer’s disease. Neuroscience 160:427–433PubMedCrossRefGoogle Scholar
  25. 25.
    Zaheer S, Thangavel R, Wu Y, Khan MM, Kempuraj D et al (2013) Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer’s disease mice. Neurochem Res 38:218–225PubMedCrossRefGoogle Scholar
  26. 26.
    Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW (1991) The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1:103–116PubMedCrossRefGoogle Scholar
  27. 27.
    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259PubMedCrossRefGoogle Scholar
  28. 28.
    Braak H, Braak E (1995) Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging 16:271–278PubMedCrossRefGoogle Scholar
  29. 29.
    Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ et al (2005) Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J Neuroinflammation 2:23PubMedCrossRefGoogle Scholar
  30. 30.
    Rubio-Perez JM, Morillas-Ruiz JM (2012) A review: inflammatory process in Alzheimer’s disease, role of cytokines. Sci World J 2012:756357CrossRefGoogle Scholar
  31. 31.
    Takashima A (2010) Tau aggregation is a therapeutic target for Alzheimer’s disease. Curr Alzheimer Res 7:665–669PubMedCrossRefGoogle Scholar
  32. 32.
    Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS et al (2001) MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Aging 22:747–754PubMedCrossRefGoogle Scholar
  33. 33.
    Apostolova LG, Lu PH, Rogers S, Dutton RA, Hayashi KM et al (2006) 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 20:224–231PubMedCrossRefGoogle Scholar
  34. 34.
    Scher AI, Xu Y, Korf ES, White LR, Scheltens P et al (2007) Hippocampal shape analysis in Alzheimer’s disease: a population-based study. Neuroimage 36:8–18PubMedCrossRefGoogle Scholar
  35. 35.
    Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT (2009) Age, Alzheimer disease, and brain structure. Neurology 73:1899–1905PubMedCrossRefGoogle Scholar
  36. 36.
    deToledo-Morrell L, Stoub TR, Wang C (2007) Hippocampal atrophy and disconnection in incipient and mild Alzheimer’s disease. Prog Brain Res 163:741–753PubMedCrossRefGoogle Scholar
  37. 37.
    Devanand DP, Pradhaban G, Liu X, Khandji A, De Santi S et al (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68:828–836PubMedCrossRefGoogle Scholar
  38. 38.
    Villain N, Desgranges B, Viader F, de la Sayette V, Mezenge F et al (2008) Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer’s disease. Neuroscience 28:6174–6181PubMedCrossRefGoogle Scholar
  39. 39.
    Lim R, Hicklin DJ, Miller JF, Williams TH, Crabtree JB (1987) Distribution of immunoreactive glia maturation factor-like molecule in organs and tissues. Brain Res 430:93–100PubMedGoogle Scholar
  40. 40.
    Wang BR, Zaheer A, Lim R (1992) Polyclonal antibody localizes glia maturation factor beta-like immunoreactivity in neurons and glia. Brain Res 591:1–7PubMedCrossRefGoogle Scholar
  41. 41.
    Zaheer A, Fink BD, Lim R (1993) Expression of glia maturation factor beta mRNA and protein in rat organs and cells. J Neurochem 60:914–920PubMedCrossRefGoogle Scholar
  42. 42.
    Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer’s disease. Neurobiol Dis 37:503–509PubMedCrossRefGoogle Scholar
  43. 43.
    Shepherd CE, Grace EM, Mann DM, Halliday GM (2007) Relationship between neuronal loss and ‘inflammatory plaques’ in early onset Alzheimer’s disease. Neuropathol Appl Neurobiol 33:328–333PubMedCrossRefGoogle Scholar
  44. 44.
    Tan B, Choi RH, Chin TJ, Kaur C, Ling EA (2012) Manipulation of microglial activity as a therapy for Alzheimer’s disease. Front Biosci 4:1402–1412CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (Ouside the USA) 2013

Authors and Affiliations

  • Ramasamy Thangavel
    • 1
    • 2
  • Duraisamy Kempuraj
    • 1
    • 2
  • Deirdre Stolmeier
    • 2
  • Poojya Anantharam
    • 2
  • Mohammad Khan
    • 2
  • Asgar Zaheer
    • 1
    • 2
  1. 1.Veterans Affairs Health Care SystemIowa CityUSA
  2. 2.Division of Neurochemistry and Neurobiology, Department of Neurology, Carver College of MedicineThe University of Iowa Hospitals and ClinicsIowa CityUSA

Personalised recommendations